No Data
No Data
Novartis' Pluvicto Expected to Dominate Prostate Cancer Radiopharmaceutical Market
Jefferies Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $56
Jefferies analyst Kelly Shi maintains $Bicycle Therapeutics(BCYC.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 43.5% and
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Radnet (RDNT)
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $32 to $55
On Sep 16, major Wall Street analysts update their ratings for $Bicycle Therapeutics(BCYC.US)$, with price targets ranging from $32 to $55.TD Cowen analyst Tara Bancroft maintains with a buy rating.
Bicycle Therapeutics (BCYC) Receives a Buy From TD Cowen
Reported Saturday, Bicycle Therapeutics Announced Updated Phase 1/2 Results For Zelenectide Pevedotin (Formerly BT8009) In Metastatic Urothelial Cancer, BT5528 In Advanced Solid Tumors And BT7480 In Advanced Solid Tumors